Lyme Disease VLA15 Vaccine Phase III — PatSnap Eureka
Lyme Disease VLA15 Vaccine: Phase III Readout & the Race for the First Tick-Borne Vaccine in Decades
Pfizer and Valneva's VLA15 is the most advanced Lyme disease vaccine candidate in a generation. Explore the science, patent landscape, and pipeline intelligence behind this landmark Phase III programme — powered by PatSnap Eureka.
Why the World Needs a New Lyme Disease Vaccine
Lyme disease is the most common vector-borne disease in the Northern Hemisphere, caused by Borrelia burgdorferi sensu lato bacteria transmitted through the bite of infected Ixodes ticks. According to the US Centers for Disease Control and Prevention, an estimated 476,000 Americans are diagnosed and treated for Lyme disease each year, while European surveillance bodies report tens of thousands of additional confirmed cases annually across endemic regions.
The last licensed Lyme disease vaccine — GlaxoSmithKline's LYMErix — was withdrawn from the US market in 2002 amid commercial pressures and public controversy, leaving more than two decades without a preventive option. During this period, the geographic range of Ixodes scapularis and Ixodes ricinus ticks has expanded significantly, driven by climate change and shifts in land use, increasing human exposure risk. The European Centre for Disease Prevention and Control has flagged tick-borne diseases as a growing public health priority.
This unmet need has driven renewed investment in Lyme disease vaccine development, with the Pfizer–Valneva collaboration on VLA15 representing the most advanced clinical programme. PatSnap's life sciences intelligence platform enables R&D teams to monitor the full competitive landscape around this programme — from patent filings to clinical publications.
How VLA15 Works: OspA Multivalent Technology
VLA15 uses a recombinant protein approach targeting outer surface protein A (OspA) across six Borrelia serotypes, providing broad geographic coverage against the most clinically relevant strains in North America and Europe.
Blocking Transmission at the Source
OspA is expressed by Borrelia bacteria while they reside in the midgut of the feeding tick. Anti-OspA antibodies generated by vaccination are taken up by the tick during feeding, neutralising the pathogen before it can migrate to the tick's salivary glands and be transmitted to the human host. This pre-transmission block is the key mechanistic advantage of OspA-based vaccines.
Pre-transmission neutralisationSix-Serotype Multivalent Formulation
Borrelia species causing Lyme disease are divided into OspA serotypes (ST1–ST6). ST1 predominates in North America (B. burgdorferi sensu stricto), while ST2–ST6 are associated with European species including B. afzelii and B. garinii. VLA15's multivalent formulation is designed to provide protection across all major clinically relevant serotypes, making it suitable for both US and European markets.
ST1–ST6 coverageRecombinant Protein with Adjuvant
VLA15 is a recombinant subunit vaccine using lipidated OspA proteins adjuvanted with aluminium hydroxide. The lipidation of OspA proteins is a critical manufacturing and immunogenicity consideration, as it mimics the natural presentation of OspA on the bacterial outer membrane, enhancing antibody responses. This approach builds on the scientific foundation of LYMErix while advancing the antigen breadth.
Aluminium hydroxide adjuvantThree-Dose Primary Series
Phase II studies evaluated VLA15 in a three-dose primary immunisation schedule, with doses administered at months 0, 2, and 6 — timed to generate peak antibody titres ahead of the peak tick season. The Phase III VALOR trial is evaluating this schedule in adults and children aged 5 years and older, with a particular focus on achieving protective antibody levels before the high-risk spring and summer tick activity period.
0, 2, 6 month scheduleLyme Disease Vaccine Landscape: Key Data Points
Visualising the public health burden and the scientific breadth of the VLA15 multivalent approach — data drawn from CDC surveillance and published clinical literature.
US Lyme Disease Reported Cases — Annual Trend
CDC confirmed case counts show a rising trajectory, with 2022 reporting 62,473 confirmed and probable cases — underscoring the vaccine's commercial and public health rationale.
VLA15 Multivalent Coverage: OspA Serotypes by Geographic Region
VLA15 targets six OspA serotypes — one dominant in North America (ST1) and five covering European Borrelia species (ST2–ST6) — enabling a single vaccine for global deployment.
The VALOR Trial: What's at Stake in Phase III
The pivotal VALOR efficacy study is the decisive test for VLA15 — its design, endpoints, and population coverage will determine regulatory success and commercial viability across two major markets.
Trial Design & Enrolment
VALOR (VALidation Of efficacy foR Lyme disease) is a randomised, placebo-controlled, observer-blind Phase III study enrolling approximately 6,000 participants aged 5 years and older. Sites span Lyme-endemic regions across the northeastern and mid-Atlantic United States, as well as endemic areas in Europe, ensuring the trial captures the full geographic and serotype diversity relevant to the multivalent formulation.
Primary Efficacy Endpoint
The primary endpoint is vaccine efficacy against confirmed Lyme disease — defined by both physician-confirmed erythema migrans (the hallmark bull's-eye rash) and laboratory-confirmed disseminated Lyme disease. This dual-confirmation approach is designed to satisfy FDA and EMA regulatory requirements for a stringent, clinically meaningful efficacy demonstration that goes beyond immunogenicity alone.
The VLA15 Patent Landscape: What IP Teams Need to Know
The intellectual property landscape surrounding Lyme disease vaccines is complex, spanning foundational OspA antigen patents, adjuvant formulation filings, manufacturing process claims, and combination vaccine applications. Valneva's core VLA15 patent estate covers the multivalent OspA antigen design and specific lipidation chemistry, while Pfizer's contribution includes manufacturing scale-up and combination vaccine platform filings. Understanding this layered IP landscape is essential for any organisation working in the tick-borne disease space.
Key patent categories to monitor include: OspA antigen sequence and variant claims, aluminium adjuvant formulation patents, cold-chain and thermostability filings, combination vaccine applications (particularly pairing Lyme with other tick-borne disease antigens), and biosimilar/follow-on vaccine freedom-to-operate analysis. The World Intellectual Property Organization PCT database contains numerous international filings relevant to this space.
PatSnap's IP analytics tools allow life sciences teams to map the full citation network around VLA15 core patents, identify white spaces for next-generation Lyme vaccine innovation, and run freedom-to-operate screens across 120+ patent jurisdictions — capabilities that are critical as the programme approaches regulatory submission and potential licensing discussions intensify.
For organisations tracking biosimilar or follow-on vaccine opportunities, understanding the patent expiry timeline across Valneva's and Pfizer's joint portfolio is essential strategic intelligence. PatSnap customers in the vaccine space use Eureka to accelerate exactly this type of competitive IP analysis.
Beyond VLA15: The Broader Tick-Borne Disease Vaccine Pipeline
VLA15 is the most advanced Lyme vaccine candidate, but the tick-borne disease vaccine landscape extends to multiple pathogens and platform approaches that R&D teams should monitor.
Track Every Lyme & Tick-Borne Vaccine Filing
PatSnap Eureka monitors patent filings, clinical trial registrations, and scientific publications across 120+ countries — updated continuously.
Lyme Disease VLA15 Vaccine — Key Questions Answered
VLA15 (now known as lyme disease vaccine candidate mRNA-1982 in some contexts, but commercially referred to as VLA15) is a recombinant protein-based Lyme disease vaccine co-developed by Pfizer and Valneva. It targets outer surface protein A (OspA) of Borrelia burgdorferi, the bacterium responsible for Lyme disease, and is the most advanced Lyme disease vaccine candidate in clinical development, having entered Phase III trials.
Lyme disease is the most common vector-borne disease in the Northern Hemisphere, with hundreds of thousands of cases reported annually in the United States and Europe. The last approved Lyme disease vaccine, LYMErix, was withdrawn from the US market in 2002. Decades without a licensed vaccine have left a significant public health gap as Ixodes tick populations expand due to climate and land-use changes.
OspA (outer surface protein A) is expressed by Borrelia bacteria while they reside inside the tick gut. A vaccine generating antibodies against OspA can neutralise the pathogen within the tick before it is transmitted to the human host during a bite. VLA15 uses a multivalent OspA formulation covering six serotypes of Borrelia to broaden geographic protection across North America and Europe.
VALOR is the pivotal Phase III efficacy trial for VLA15, enrolling approximately 6,000 participants aged 5 years and older across Lyme-endemic regions in the United States and Europe. The trial evaluates vaccine efficacy against confirmed Lyme disease, with primary endpoint readout expected in the mid-2020s. Positive results would support regulatory submissions to the FDA and EMA.
PatSnap Eureka provides AI-powered patent and literature search across more than 2 billion data points covering 120+ countries. Researchers can map the VLA15 patent portfolio, identify freedom-to-operate risks, track competitor filings in the Lyme disease vaccine space, and monitor clinical trial publications — all in a single platform designed for life sciences R&D teams.
Beyond Lyme disease, tick-borne encephalitis (TBE) vaccines are already licensed in Europe and Asia. Emerging pipeline candidates target tick-borne diseases including anaplasmosis, babesiosis, and Powassan virus. Anti-tick vaccines targeting tick salivary proteins represent a broader platform approach that could provide cross-protection against multiple pathogens transmitted by Ixodes and other tick species.
Still have questions? Let PatSnap Eureka search the science for you.
Ask Eureka AI About VLA15Accelerate Your Lyme Disease & Vaccine Research with AI Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, track clinical pipelines, and identify white spaces — 75% faster than traditional research methods.
References
- CDC — Lyme Disease Surveillance and Statistics
- European Centre for Disease Prevention and Control — Lyme Borreliosis
- World Health Organization — Vector-Borne Diseases Fact Sheet
- NIH — Lyme Disease Vaccine Candidate Research
- ClinicalTrials.gov — VALOR Phase III VLA15 Study (NCT04921072)
- WIPO PATENTSCOPE — International Patent Database
- PatSnap — Life Sciences Innovation Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.